Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | LSS | P48449 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904840 | 0.84 | SIGMAR1 (0.53) | SIGMAR1POLBBCHEACHEBACE1 | |
| SCHEMBL19087066 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KDM4ESIGMAR1LSSMEN1 | |
| SCHEMBL19116434 | 0.80 | ALDH1A1 (0.47) | ALDH1A1KDM4ESIGMAR1LSSMEN1 | |
| SCHEMBL19077903 | 0.79 | ALDH1A1 (0.46) | ALDH1A1KDM4ESIGMAR1LSSMEN1 | |
| SCHEMBL979535 | 0.74 | ALDH1A1 (0.67) | ALDH1A1KDM4ESIGMAR1LSSMEN1 | |
| SCHEMBL25799682 | 0.72 | SIGMAR1 (0.43) | SIGMAR1DRD2 | |
| SCHEMBL15901736 | 0.72 | ALDH1A1 (0.71) | ALDH1A1KDM4ESIGMAR1LSSMEN1 | |
| SCHEMBL24482888 | 0.71 | — | — | |
| SCHEMBL7937990 | 0.69 | ALDH1A1 (0.95) | ALDH1A1KDM4ESIGMAR1LSSPOLB | |
| SCHEMBL23851111 | 0.69 | ALDH1A1 (0.87) | ALDH1A1KDM4ESIGMAR1LSSMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792256-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3400221-B1 | PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | ALDH1A1 2997/4885KDM4E 2506/4885SIGMAR1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.